Evaluation of The Impact of Favipiravir Therapy on Laboratory Parameters in Patients with Chronic Kidney Disease Diagnosed with COVID-19” : A Retrospective Single Centre Study

OpenAlex İngilizce

Aim: Favipiravir, initially developed for influenza, is a potential treatment for COVID-19. However, safety data for favipiravir in patients with chronic renal failure is limited. This study examined its effects on laboratory parameters in COVID-19 patients both with and without chronic kidney disease (CKD), addressing the challenges posed by renal health impairment.Material and Methods: This retrospective study examined 339 eligible PCR-positive COVID-19 inpatients, selected from an initial 559 participants, at a Turkish tertiary care hospital. The patients were grouped based on estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² and ≥ 60 mL/min/1.73 m² (control group). Clinical, demographic, and laboratory characteristics were compared using parametric and nonparametric tests, with statistical significance set at p